Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Dana-Farber Cancer Institute
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Patrick Y. Wen, MD, Dana-Farber/Brigham and Women's Cancer Center
ClinicalTrials.gov Identifier:
NCT01339039
First received: April 6, 2011
Last updated: June 13, 2014
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2015
  Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)